Ligand Pharmaceuticals (LGND) Earnings Date & Reports

Key Takeaways

• Reporting Date: Ligand Pharmaceuticals is scheduled to report second quarter 2026 financial results on Thursday, August 6, 2026, before the market opens, with a conference call at 8:30 a.m. Eastern Time.
• Consensus Estimates: Analysts expect adjusted earnings per share (EPS) of approximately $1.99 and revenue of roughly $63 million for the second quarter, according to consensus data compiled from multiple research firms.
• Prior Quarter Recap: In Q1 2026, Ligand reported adjusted EPS of $1.63 on total revenue of $51.7 million, missing consensus estimates and triggering a roughly 9.6% post-earnings stock decline.
• Royalty Growth Engine: Royalty revenue surged 56% year-over-year in Q1 2026 to $43 million, driven by Filspari, Ohtuvayre, and Capvaxive — a growth trajectory investors will closely monitor in Q2.
• XOMA Acquisition Catalyst: The pending acquisition of XOMA Royalty Corporation, announced in April 2026, remains the dominant strategic narrative and is expected to close in the third quarter, adding over 120 assets to Ligand's royalty portfolio.
• Filspari FSGS Approval: The FDA's full approval of Filspari for focal segmental glomerulosclerosis (FSGS) in April 2026 represents a major commercial expansion for Ligand's largest royalty asset.

Earnings Context and Why It Matters

Ligand Pharmaceuticals' Q2 2026 report arrives at a pivotal moment. The company has executed a multi-year transformation into a pure-play royalty aggregator, shedding infrastructure-heavy operations to focus on high-margin royalty streams. The upcoming results will test whether the 56% year-over-year royalty revenue growth seen in Q1 can be sustained, especially after last quarter's earnings miss rattled investor confidence. More critically, this report serves as the last earnings checkpoint before the expected close of the transformative XOMA Royalty acquisition, a deal that would nearly double Ligand's commercial-stage asset count and significantly diversify its revenue base. With the stock trading at elevated multiples relative to historical levels, investors need evidence that organic royalty momentum remains intact alongside the inorganic growth narrative.

Earnings Expectations

Wall Street consensus points to adjusted EPS of approximately $1.99 for the second quarter of 2026, with revenue estimates clustering around $63 million, according to data from Yahoo Finance, MarketBeat, and Finviz. These figures would represent significant growth from the year-ago period, when Ligand delivered adjusted EPS of $1.60 on total revenue of $47.6 million — driven at that time by $36.4 million in royalty revenue.

On a sequential basis, Q2 estimates imply meaningful acceleration from the $51.7 million in revenue and $1.63 in adjusted EPS reported in Q1 2026. The expected quarter-over-quarter revenue jump of roughly 22% likely reflects continued volume growth from key commercial royalty products — particularly Filspari, which became Ligand's largest royalty contributor in Q1 — as well as potential improvements in Captisol® (a solubility-enhancing excipient used in multiple FDA-approved drugs) order timing, which has historically exhibited quarter-to-quarter lumpiness.

Analysts will scrutinize royalty revenue performance above all else. In Q1, royalties reached $43 million, representing 83% of total revenue. Maintaining or exceeding that run rate in Q2 would validate management's thesis that the royalty portfolio can deliver compounding growth. Consensus estimates also suggest that adjusted EPS of $1.99 would mark approximately 24% growth compared to the $1.60 reported in Q2 2025. GAAP net income may again diverge materially from adjusted figures due to non-cash fair value adjustments on equity holdings, including Ligand's investment in Pelthos Therapeutics.

Beyond the headline numbers, investors will parse Captisol sales trends (Q1 saw a decline to $8.7 million from $13.5 million year-over-year due to order timing), contract revenue, and any updates on the XOMA transaction timeline. The company's reaffirmed full-year 2026 guidance — calling for total revenue of $270 million to $310 million and adjusted EPS of $8.50 to $9.50, incorporating an anticipated partial-year XOMA contribution — will also be under the microscope.

AI Screener

Identifying earnings-driven opportunities in a market of thousands of stocks requires speed and precision. Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamental data, trend analysis, volatility metrics, and proprietary AI-driven signals. Users can scan thousands of equities using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, and performance benchmarks to surface trade ideas, breakout candidates, and trending names far more efficiently than manual screening allows. Whether tracking earnings season movers like LGND or scanning for emerging patterns across sectors, the AI Screener streamlines the discovery process. Explore the AI Screener to see how data-driven filtering can sharpen your market research.

Market Reaction and Investor Sentiment

Sentiment heading into Q2 earnings is cautiously optimistic but tinged with the memory of Q1's disappointment. In May, Ligand shares fell approximately 9.6% in the session following its Q1 2026 report, when adjusted EPS of $1.63 missed the consensus estimate of roughly $1.84 and revenue of $51.7 million came in below the approximately $59 million expected. The miss was partly attributed to lower-than-anticipated Captisol sales and contract revenue timing, while the core royalty business actually exceeded some internal expectations.

Since that pullback, shares have recovered ground, buoyed by a series of positive developments: the XOMA acquisition announcement, full FDA approval of Filspari for FSGS, and positive Phase III data from Palvella Therapeutics' QTORIN™ rapamycin program for microcystic lymphatic malformations (MLMs) — an asset in which Ligand holds royalty rights. The stock's recovery suggests that investors are looking past the Q1 headline miss and focusing on the broader strategic picture.

Key risk factors heading into the Q2 print include potential continued lumpiness in Captisol orders, the possibility of non-cash accounting volatility tied to equity-method investments, and broader biotech sector sentiment. A royalty revenue figure above $45 million and adjusted EPS meeting or exceeding the $1.99 consensus would likely be viewed favorably, while any shortfall in royalty growth trajectory could amplify questions about whether organic momentum is sufficient to justify the stock's valuation ahead of the XOMA integration.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, investors should focus on several interconnected themes that will shape Ligand's trajectory through the remainder of 2026 and into 2027.

XOMA Acquisition Close and Integration. The single most consequential near-term catalyst is the expected third-quarter close of the XOMA Royalty acquisition. Upon closing, the combined entity would hold economic interests in more than 200 development and commercial-stage assets, including seven additional commercial products such as Vabysmo, Ojemda, and Miplyffa. Management has guided that XOMA will contribute approximately $0.50 to adjusted EPS in the partial-year 2026 period and approximately $1.50 in 2027. Any update on the transaction timeline, regulatory approvals, or integration planning during the earnings call will be closely parsed. The deal also brings tax attributes — including net operating losses and R&D tax credits — that are expected to enhance combined operating cash flow to approximately $300 million in 2027.

Filspari's FSGS Commercial Launch. Following full FDA approval in April 2026, Filspari is now the first and only approved therapy for FSGS, a rare and serious kidney disease affecting an estimated 30,000 patients in the United States. Travere Therapeutics, Ligand's partner, has a dedicated nephrology sales force of over 100 representatives and significant prescriber overlap with the existing IgA nephropathy (IgAN) indication. Management noted that FSGS patients began treatment within the first week of approval. The pace of FSGS adoption in the second half of 2026 will be a critical barometer for Ligand's largest royalty asset.

Pipeline Catalysts and Partner Progress. Palvella Therapeutics is expected to submit a New Drug Application (NDA) for QTORIN rapamycin in MLMs in the second half of 2026. Ligand estimates this program could generate $100 million to $300 million in peak annual royalties. Additionally, Mirum Pharmaceuticals' volixibat for primary sclerosing cholangitis (PSC) — which reported positive Phase IIb data — could see an NDA submission this year, representing another potential royalty asset for the post-XOMA portfolio. On the regulatory front, Ohtuvayre's approval decision in China and Filspari's regulatory progress in Japan represent geographic expansion opportunities.

Balance Sheet and Capital Deployment. Ligand ended Q1 2026 with approximately $780 million in cash, cash equivalents, and short-term investments, alongside a $200 million undrawn revolving credit facility. Management has articulated a capital deployment strategy targeting $150 million to $250 million annually in new royalty opportunities. How the company balances the XOMA integration with its ongoing deal pipeline will influence the pace of portfolio expansion and long-term earnings compounding.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations